US COST-EFFECTIVENESS OF LENACAPAVIR PLUS OPTIMIZED BACKGROUND REGIMEN VERSUS OTHER TREATMENTS FOR MULTI-DRUG RESISTANT HIV

被引：0
|
作者：
Vardanega, V. [1 ]
New, E. [1 ]
Mezzio, D. [2 ]
Eddowes, L. A. [1 ]
机构：
[1] Costello Med, London, England
[2] Gilead Sci, Foster City, CA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE472
引用
收藏
页码：S145 / S145
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of adding novel or Group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany
    Wirth, Daniel
    Dass, Ramesh
    Hettle, Robert
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [22] Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany
    Wirth, Daniel
    Dass, Ramesh
    Hettle, Robert
    BMC HEALTH SERVICES RESEARCH, 2017, 17
  • [23] COST-EFFECTIVENESS OF ADDING NOVEL OR GROUP 5 INTERVENTIONS TO A BACKGROUND REGIMEN FOR THE TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS IN GERMANY
    Wirth, D.
    Dass, R.
    Hettle, R.
    VALUE IN HEALTH, 2016, 19 (07) : A588 - A588
  • [24] Systematic Review of Cost-Effectiveness Analysis for Surgical and Neurostimulation Treatments for Drug-Resistant Epilepsy in Adults
    Kee, Nicholas Ngan
    Foster, Emma
    Marquina, Clara
    Tan, Andy
    Pang, Samantha S. T.
    O'Brien, Terence J.
    Kwan, Patrick
    Jackson, Graeme D.
    Chen, Zhibin
    Ademi, Zanfina
    NEUROLOGY, 2023, 100 (18) : E1866 - E1877
  • [25] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFOZIN VERSUS OTHER T2DM TREATMENTS IN THE SPANISH CONTEXT
    Abad Paniagua, E. J.
    Casado Escribano, P.
    Fernandez Rodriguez, J. M.
    Morales Escobar, F. J.
    Canal Fontcuberta, C.
    Betegon Nicolas, L.
    Capel, M.
    Brosa, M.
    VALUE IN HEALTH, 2013, 16 (07) : A439 - A439
  • [26] Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration
    Chen, Rui
    Wu, Bin
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (15)
  • [27] Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
    Zhong, Jiayun
    Liu, Yu
    Fu, Qian
    Huang, Dan
    Gong, Wenjun
    Zou, Jian
    CANCER MANAGEMENT AND RESEARCH, 2024, 16 : 593 - 602
  • [28] Cost-Effectiveness of Continuous Positive Airway Pressure Therapy Versus Other Treatments of Obstructive Sleep Apnea
    Weingarten, Jeremy A.
    SLEEP MEDICINE CLINICS, 2022, 17 (04) : 559 - 567
  • [29] Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 52 Results
    Ogbuagu, Onyema
    Segal-Maurer, Sorana
    Trottier, Benoit
    Shirasaka, Takuma
    Koenig, Ellen L.
    Hoffmann, Christian
    Wang, Hui
    Margot, Nicolas A.
    Dvory-Sobol, Hadas
    Rhee, Martin S.
    Baeten, Jared
    Molina, Jean-Michel
    HIV MEDICINE, 2023, 24 : 59 - 60
  • [30] New drug treatments versus structured education programmes for type 2 diabetes: comparing cost-effectiveness
    Khunti, Kamlesh
    Chatterjee, Sudesna
    Carey, Marian
    Daly, Heather
    Batista-Ferrer, Harriet
    Davies, Melanie J.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (07): : 557 - 559
12345